Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T15:15:48.228Z Has data issue: false hasContentIssue false

Mood Stabilizers

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 217 - 237
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Novartis Pharmaceutical Corporation. (2007). Tegretol-XR Package Insert. East Hanover, New Jersey.Google Scholar
Validus Pharmaceuticals LLC. (2007). Equetro Package Insert. Parsippany, New Jersey.Google Scholar
Teva Pharmaceuticals USA Inc. (2018). Epitol Package Insert. North Wales, Pennsylvania.Google Scholar
Novartis Pharmaceutical Corporation. (2020). Tegretol Package Insert. East Hanover, New Jersey.Google Scholar
Shire US Inc. (2020). Carbatrol Package Insert. Lexington, Massachusetts.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Carbamazepine Protocol. Sacramento, California.Google Scholar
Capule, F., Tragulpiankit, P., Mahasirimongkol, S., et al. (2020). Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. Pharmacogenomics J, 20, 533–541.CrossRefGoogle ScholarPubMed
Soria, A., Bernier, C., Veyrac, G., et al. (2020). Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. J Am Acad Dermatol, 82, 606–611.CrossRefGoogle ScholarPubMed
Birnbaum, A. K., Meador, K. J., Karanam, A., et al. (2020). Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol, 77, 441–450.CrossRefGoogle ScholarPubMed

References

GlaxoSmithKline LLC. (2009). Lamictal Package Insert. Research Triangle Park, North Carolina.Google Scholar
GlaxoSmithKline LLC. (2019). Lamictal XR Package Insert. Research Triangle Park, North Carolina.Google Scholar
OWP Pharmaceuticals Inc. (2020). Subvenite Package Insert. North Paerville, Illinois.Google Scholar
Sills, G. J., Rogawski, M. A. (2020). Mechanisms of action of currently used antiseizure drugs. Neuropharmacology, 168, 107966.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Lamotrigine Protocol. Sacramento, California.Google Scholar
Li, Y., Zhang, F., Xu, Y., et al. (2018). Pharmacokinetics, safety, and tolerability of lamotrigine chewable/dispersible tablet following repeat-dose administration in healthy Chinese volunteers. Clin Pharmacol Drug Dev, 7, 627–633.CrossRefGoogle ScholarPubMed
Nevitt, S. J., Tudur Smith, C., Weston, J., et al. (2018). Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev, 6, CD001031.Google ScholarPubMed
Tawhari, I., Tawhari, F., Aljuaid, M. (2018). Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection. BMJ Case Rep, 2018, 2018, brc2017222416.Google ScholarPubMed
Vazquez, M., Maldonado, C., Guevara, N., et al. (2018). Lamotrigine-valproic acid interaction leading to Stevens-Johnson syndrome. Case Rep Med, 2018, 5371854.CrossRefGoogle ScholarPubMed
Oya, K., Sakuma, K., Esumi, S., et al. (2019). Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacol Rep, 39, 241–246.CrossRefGoogle ScholarPubMed
Panebianco, M., Bresnahan, R., Ramaratnam, S., et al. (2020). Lamotrigine add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 3, CD001909.Google ScholarPubMed
Pensel, M. C., Nass, R. D., Tauboll, E., et al. (2020). Prevention of sudden unexpected death in epilepsy: current status and future perspectives. Expert Rev Neurother, 20, 497–508.CrossRefGoogle ScholarPubMed
Stephen, L. J., Brodie, M. J. (2020). Pharmacological management of the genetic generalised epilepsies in adolescents and adults. CNS Drugs, 34, 147–161.CrossRefGoogle ScholarPubMed

References

ANI Pharmaceuticals Inc. Lithobid Package Insert. Baudette, Minnesota.Google Scholar
Calabrese, J. R., Shelton, M. D., Rapport, D. J., et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry, 162, 2152–2161.CrossRefGoogle ScholarPubMed
Kemp, D. E., Gao, K., Ganocy, S. J., et al. (2009). A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry, 70, 113–121.CrossRefGoogle ScholarPubMed
Mission Pharmacal. (2015). Lithostat Package Insert. San Antonio, Texas.Google Scholar
West-Ward Pharmaceuticals Corp. (2019). Lithium Carbonate Package Insert. Eatontown, New Jersey.Google Scholar
Smith, K. A., Cipriani, A. (2017). Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord, 19, 575–586.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Lithium Protocol. Sacramento, California.Google Scholar
Oya, K., Sakuma, K., Esumi, S., et al. (2019). Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacol Rep, 39, 241–246.CrossRefGoogle ScholarPubMed
Undurraga, J., Sim, K., Tondo, L., et al. (2019). Lithium treatment for unipolar major depressive disorder: systematic review. J Psychopharmacol, 33, 167–176.CrossRefGoogle ScholarPubMed
Bahji, A., Ermacora, D., Stephenson, C., et al. (2020). Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord, 269, 154–184.CrossRefGoogle ScholarPubMed
Silva, E., Higgins, M., Hammer, B., et al. (2020). Clozapine rechallenge and initiation despite neutropenia – a practical, step-by-step guide. BMC Psychiatry, 20, 279.CrossRefGoogle ScholarPubMed

References

AbbVie Inc. (2020). Depakote Package Insert. North Chicago, Illinois.Google Scholar
AbbVie Inc. (2020). Depakote Sprinkles Package Insert. North Chicago, Illinois.Google Scholar
AbbVie Inc. (2020). Depakote ER Package Insert. North Chicago, Illinois.Google Scholar
Zydus Pharmaceuticals (USA) Inc. (2020). Divalproex Package Insert. Pennington, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Valproic Acid/Divalproex Protocol. Sacramento, California.Google Scholar
Lonergan, E. T., Cameron, M., Luxenberg, J. (2004). Valproic acid for agitation in dementia. Cochrane Database Syst Rev, CD003945.CrossRefGoogle Scholar
Sykes, L., Wood, E., Kwan, J. (2014). Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev, CD005398.CrossRefGoogle Scholar
Trinka, E., Hofler, J., Zerbs, A., et al. (2014). Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs, 28, 623–639.CrossRefGoogle ScholarPubMed
Hayes, J. F., Marston, L., Walters, K., et al. (2016). Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med, 13, e1002058.CrossRefGoogle ScholarPubMed
Nevitt, S. J., Sudell, M., Weston, J., et al. (2017). Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 12, CD011412.Google ScholarPubMed
Thomson, S. R., Mamulpet, V., Adiga, S. (2017). Sodium valproate induced alopecia: a case series. J Clin Diagn Res, 11, FR01–FR02.Google ScholarPubMed
Baillon, S. F., Narayana, U., Luxenberg, J. S., et al. (2018). Valproate preparations for agitation in dementia. Cochrane Database Syst Rev, 10, CD003945.Google ScholarPubMed
Graham, R. K., Tavella, G., Parker, G. B. (2018). Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Affect Disord, 228, 216–221.Google Scholar
Baudou, E., Benevent, J., Montastruc, J. L., et al. (2019). Adverse effects of treatment with valproic acid during the neonatal period. Neuropediatrics, 50, 31–40.Google ScholarPubMed
Baumgartner, J., Hoeflich, A., Hinterbuchinger, B., et al. (2019). Fulminant onset of valproate-associated hyperammonemic encephalopathy. Am J Psychiatry, 176, 900–903.CrossRefGoogle ScholarPubMed
Jochim, J., Rifkin-Zybutz, R. P., Geddes, J., et al. (2019). Valproate for acute mania. Cochrane Database Syst Rev, 10, CD004052.Google ScholarPubMed
Chakrabarty, T., Keramatian, K., Yatham, L. N. (2020). Treatment of mixed features in bipolar disorder: an updated view. Curr Psychiatry Rep, 22, 15.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Mood Stabilizers
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Mood Stabilizers
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Mood Stabilizers
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×